Results were presented in a late breaking clinical trial session at ACC.14 with simultaneous publication in the New England Journal of Medicine. Results demonstrate how the CoreValve design delivers performance that matters most to both physicians and their patients.
The results demonstrate how the CoreValve design achieves high survival rates and low rates of stroke and paravalvular leakage in complex and frail patients.
CoreValve and CoreValve Evolut—the first and only TAVI devices to receive an indication for use in degenerative surgical bioprostheses—now provide options for patients at high operative risk for redo surgery.
New data presented at EuroPCR 2013 shows favorable 1 year outcomes with high survival rates, low and stable rates of stroke, and significant and sustained hemodynamic improvement.